



# Annual Meeting: Advancing Science, Improving Lives

Carol Malysz, Executive Director  
& RI Bio Board of Directors

[carolmalysz@ri-bio.org](mailto:carolmalysz@ri-bio.org) | 401.400.5499 | [ri-bio.org](http://ri-bio.org)



## Meeting Agenda

9:30 - 11:00 am

RI Life Sciences Ecosystem/RI Bio Progress –  
Carol Malysz, Executive Director, RI Bio

Reflections on Life Science Progress – Patrice Milos, PhD,  
RI Bio Board Chair

Remarks on Scientific Advancement & Future Direction–  
Jaimy Mauricio – Incoming Board Chair



# RI Bio

Growing Our  
Life Sciences  
Economy

As the state affiliate of the world's largest biotech  
advocacy organization,



**Biotechnology**  
Innovation Organization

*RI Bio's mission is to grow the life sciences economy in  
Rhode Island & Southeastern New England*

# **RI Bio** LEADERSHIP & BOARD



**Carol Malysz, MBA**  
Executive Director  
RI Bio




**Guy Asadorian**  
SVP and Private Client  
Advisor, Bank of America  
Private Bank



**Michael Elliott, MBBS,  
PhD, FRCAP**  
Physician-Scientist, Drug  
Developer, Early-Stage Life  
Science Investor



**Margaret Farrell, JD**  
Partner, Hinckley Allen



**Michael Katz, PhD**  
Life Sciend Advisor,  
Intellectual Propoerty &  
Economic Development



**Jamy Mauricio, MBA**  
Senior Director Financial  
Planning & Analysis,  
Intellia Therapeutics, Inc.



**Dom Messerli, MBA**  
CEO,  
Lenoss Medical



**Patrice Milos, PhD**  
RI Bio Board Chair  
Senior Advisor



**Indra Neil Sarkar, PhD**  
President & CEO,  
Rhode Island Quality  
Institute



**Jeff Vallerga**  
Vice President, Business  
Development, BIO Business  
Solutions



**Michelle Wu, MSCEP**  
Medical Device Leader  
Management Consultant,  
Wu Consulting





**Stacey Carter**, Training Director – Project Management Essentials, Advanced Project Management & Reskilling Training

**Kristie Stark** – Creative/Art Director

**Martha Langer** – Biotech Boot Camp Training Director

**Diane Sterrett** – Content & Creative Strategist

**Elizabeth Atalay** – Social Media Director



## INTERNS




**Kiley Flynn**  
Providence College



**Ana Rodriguez**  
Providence College



**Samantha Martin**  
Providence College



**Giada Gloria**  
Catholic University



## Life Science Advisors

**Ed Bozzi, PhD** – URI Biotech Professor (ret.)  
**Robert Bouthillier** – CEO/Co-Founder, PrO2 Health  
**Leonard Buckbinder, PhD** – Scorpion Therapeutics  
**Chesley Chen** – Principal, Life Sciences, CliftonLarsonAllen  
**Moses Goddard** – Life Sciences entrepreneur  
**Geraldine Harriman, PhD** – Co-Founder/CSO, Hot Spot Therapeutics  
**Scott Keeley** – Patent Agent, Keeley DeAngelo, LLP  
**Sean Marnane** – Director of External Manufacturing & MSAT, Be BioPharma  
**Brian Morley** – Founder, Emerge RI  
**RJ Panzo** – Sr. Director Scientific Operations, Breakthrough Properties  
**James Pierce, PhD** – ED Process Development., Amgen  
**John Thompson, PhD** – Principal Application Scientist, Nabsys  
**Michelle Wu** – Fractional COO & Medical Device Consultant, Wu Consulting

## Legislative Committee

**Joni Arvi** – Director, State Govt Affairs, Bristol Myers Squibb  
**Martha Auster** – Regional Director, Govt Affairs, Vertex  
**Caitlin Beresin** – Director, US State Affairs, J&J  
**Stephen Burm** – Director, State Govt. Affairs, NE Region, BIO  
**Ashley Calabrese** – Associate Director, State Govt Affairs, Novartis  
**Will Farrell** – Contract Lobbyist, RI  
**Chris Kent** – Sr. Mgr., State Govt Affairs Northeast, Amgen  
**Matt Meehan** – Director, State Govt Affairs, Pfizer  
**Dmitri Siegel** – Director State Govt Affairs, Alliance Development, Bristol Myers Squibb

## COMMUNITY PARTNERS

**RHODE  
ISLAND**  
COMMERCE

**RI+HUB**

**RIIC**  
RHODE ISLAND ISRAEL  
COLLABORATIVE

**SLATER**  
TECHNOLOGY FUND

**NEMIC**  
NEW ENGLAND MEDICAL  
INNOVATION CENTER

**Innovate  
Newport**

**RI**  
THE UNIVERSITY OF RHODE ISLAND

**REAL  
JOBS**  
Rhode Island

**DLT**

**SKILLS FOR  
RHODE ISLAND'S  
FUTURE**

**Cherrystone**  
Angel Group

**CiC**



**VENTURE  
CAFÉ**  
PROVIDENCE

**Bio**

**G2G CONSULTING**  
GOVERNMENT TO GROWTH

**RHODE ISLAND  
INBRE**  
Biomedical Research Excellence

**EDA**  
U.S. ECONOMIC DEVELOPMENT ADMINISTRATION



## OUR SPONSORS



BROWN



BANK OF AMERICA



U.S. ECONOMIC DEVELOPMENT ADMINISTRATION




EY

Building a better  
working world







# RI Bio

## | RI'S BIOSCIENCE ECONOMY

**5773**

Number of  
Biotechnology  
Workers

**666**

Number of  
Biotechnology  
Companies &  
Organizations

**\$95k**

Average Annual  
Salary of a  
Biotechnology  
Employee

**31%**

RI's Health & Life  
Sciences Industry  
Concentration is  
31% higher than  
the national  
average

**5**

Number of  
Institutions in RI  
Collaborating on  
Neuroscience  
Research  
(Brown, URI, Lifespan, Care NE  
and Providence VA)

## RI LIFE SCIENCE POINTS OF DISTINCTION


Rhode Island has state-wide excellence in:

- Neuroscience
- Medical Devices & Technologies
- World Class Biomanufacturing Facilities
- Cell & Gene Therapies

The Amgen logo, featuring the word "AMGEN" in a bold, blue, sans-serif font.

**XM THERAPEUTICS**






# RiBio

## STRATEGIC GOALS

- Our Mission is to grow the Life Sciences economy in Rhode Island & Southeastern New England
- Offer entrepreneurial resources & support to grow new enterprises
- Develop the workforce & grow jobs
- Build enabling infrastructure to support new company creation
- Provide access to capital to support new venture development
- Advocate for our industry at the local and national level
- Make life sciences accessible to all

# KEY ORGANIZATIONAL MILESTONES



*Growing Our Life Sciences Ecosystem*



# Significant Progress | ADVANCING ENTREPRENEURSHIP

Pro bono advisory services to more than 188 life science startups. Featured more than 70 life sciences entrepreneurs who have innovated their way from lab to market

**Quris**  
ai

COGNESY



> 188  
STARTUPS  
SERVED

 **XM THERAPEUTICS**

 **UNRAVEL**  
BIOSCIENCES

  
Stellaromics

RESEARCH INSTRUMENTS  
CORPORATION

 **H<sub>2</sub>PURE**<sup>TM</sup>

# Significant Progress | **WORKFORCE DEVELOPMENT**

More than 450 incumbent workers, individuals in transition and new hires were trained through RI Bio programs



FUNDED BY



# Significant Progress | TALENT PIPELINE

Our **Introduction to Biotechnology** and **Developing Lab Skills** courses are free for all RI Islanders to gain hands-on experience and explore family-sustaining careers in the life sciences



Graduates Sedes Nhar, Richardo Mayorga & Olayinka Olasanoye

- Learn sought-after skills
- Receive job coaching & job search help
- Meet with employers looking to hire right away
- Course includes a **FREE laptop**

Job Fair with companies looking to hire Boot Camp graduates!

## PROJECT PARTNERS



**REAL  
JOBS**  
Rhode Island



# Significant Progress | INVESTMENT



Slater Technology Fund launched [RightHill Ventures](#) in 2022 to provide seed-stage capital and other startup support targeting university research-driven ventures and founders



\$1.5 Million pre-seed convertible note financing  
\$1.8 Million NIH Small Business grant



\$12.4 Million Series A



\$4 Million Series A1



**XM THERAPEUTICS**

\$375,000 Slater investment



# Significant Progress | ADVANCING WOMEN IN SCIENCE

Our Women in Science series is designed to **educate**, **empower** and **inspire** women to advance as leaders and change agents and has featured more than 35 women leaders in Rhode Island and beyond



# Significant Progress | **LEGISLATION & ADVOCACY**

## Legislative Committee Goals:

- Helping RI Bio weigh in on legislation that affects the industry
- Working successfully with the RI state legislature
- Fostering relationships with industry patient advocacy groups
- Elevating the profile of the RI life sciences industry/RI Bio




# Significant Progress | MEMBERSHIP DEVELOPMENT

From zero to > than 224 life sciences member companies & organizations in 4 years




# Significant Progress | MEMBERSHIP DEVELOPMENT



- >5 Corp (23%)
- 5-49 Corp (24%)
- 50-199 Corp (4%)
- 200-499 Corp (2%)
- 500+ Corp (4%)
- Academic (4%)
- Service Providers (4%)
- Students (7%)
- Individuals (28%)



# Significant Progress | SUSTAINABILITY




- Grants, \$345K (68%)
- Individual Giving, \$2K (1%)
- Membership, \$33K (7%)
- Bio Business Solutions \$93K (19%)
- Sponsorships \$27K (5%)

# Significant Progress | SUSTAINABILITY

Over the next three years, RI Bio will advance on the path of self sustainability as membership, sponsor income and individual giving grows to 50% of the total annual budget

**Key to Sustaining:** Growing Members (companies, organizations, service providers, individuals) Sponsors & Philanthropic contributions



# Significant Progress | RHODE ISLAND LIFE SCIENCE HUB

## Governor's FY24 Budget - \$45M to Grow the Life Sciences Sector

State investments will support:

- Entrepreneur and Business Resources
- Workforce Development
- Space & Infrastructure



\$45M for  
Life Sciences in  
Governor's FY24 Budget

The life sciences sector is experiencing major growth, and I am very excited about Rhode Island's potential to become a hub for this sector."

RI House Speaker -  
K. Joseph Shekarchi

# Continued Progress | **ADVANCING SCIENCE, IMPROVING LIVES**

- Advance the convergence revolution in biopharma, digital health, medical devices and engineering
- Support the efforts of our new RILSH & all of our community partners in building our ecosystem
- Ensure success for Wexford/CIC & RIDOH Health Lab
- Provide companies with investment capital, resources, incentives, infrastructure and community support to grow
- Business attraction evolves naturally from Life Sciences initiatives, growth and visibility
- Make certain that everyone across the state has equal opportunity to work in Life Sciences and that diversity and opportunity become synonymous with our industry

# BIO 2024 Annual Convention







**RI Bio**

Growing Our  
Life Sciences  
Economy

# Thank you!

Carol Malysz  
Executive Director, RI Bio

[carolmalysz@ri-bio.org](mailto:carolmalysz@ri-bio.org) | 401.400.5499 | [ri-bio.org](http://ri-bio.org)



**RI Bio**

Growing Our  
Life Sciences  
Economy

# Annual Meeting: Reflections on Life Science Progress

Patrice M. Milos, Ph.D. – Board Chair

# Highlights: RI Life Sciences Ecosystem Jan 2019 - Present

**RI Bio** ReBranded Organization Launched

**RI Bio/RI Israel Collaborative:** Digital Health

**RI Bio First EIR in Place**

**RI Bio Workforce Development**

**URI \$20M INBRE Award – Partnership with RI BIO**

**REAL JOBS** Rhode Island

**NEMIC** Healthcare Innovation

**SLATER** TECHNOLOGY FUND

**RI-HUB** WHERE IDEAS GROW INTO BUSINESSES

**Non-Profit Foundation Founded**

**NEMIC Accelerator Program Launch**

**VENTURE CAFE** Growing our Life Sciences Economy

**State Health Labs/Innovation Project**

**RI Life Science Hub FY24 State Budget**

**RI Bio First Biotech Boot Camp**

**EMPOWER** PROGRAM FOR HEALTH + WELLNESS

**Innovation@Brown Showcase**

**1/19**

**7/19**

**1/20**

**7/20**

**1/21**

**7/21**

**1/22**

**7/22**

**1/23**

**7/23**

**1/24**

**Wexford Science IV: Research Instruments Corp**

**Innovation Voucher** Alcinous

**Circadian Positioning**

**Brown Biomedical Innovation: Grants Awarded Annually**

**BOLDEN**

**Vertex Acquires Semma Therapeutics for \$1B**

**Novartis Acquires Cadent Pharma for \$210M, + Up to \$560M**

**Novartis**

**Cadent Therapeutics**

**XM THERAPEUTICS**

**pedialydx** Plan: Investing in Research

**NanoDe Therapeutics** Life Sciences Bldg.

**Slater Secures \$12 SSBCI/RI Commerce Funds for Investment Capital**

**Lenoss Medical**

**BOLDEN**

**OCTAGON THERAPEUTICS**

**RI BIO | Annual Meeting | February 15<sup>th</sup>, 2024**

**Please Know This Is An Abbreviated Snapshot**


***Please Know This Is An Abbreviated Snapshot***

# Belief in Our Ecosystem: **LENOSS** MEDICAL

Demineralized surface  
allows for new bone  
formation through  
osteoconduction and  
osteoiduction



Cortical bone  
provides stability and  
high compressive  
strength



Flexible links  
enable minimally invasive  
implantation to augment a  
patient's fractured  
vertebrae with **new bone**

## OsteoPearl

Biological Allograft Chain

A demineralized, 100% cortical allograft  
Vertebral Body Augmentation (VBA) solution

Placing **Natural** bone  
where **New** bone is  
needed most.

**LENOSS**  
..... MEDICAL



Dom Messerli, Founder/CEO  
RI Bio Board Member  
NEMIC EIR

RI Company Founded: 2017

First In-Human Pilot Surgery: 2019

Cherrystone Investment: 2020

Slater Investment: 2021

Right Hill Ventures Series A Investment: 2023

RI Commerce \$50K Innovation Voucher/Brown University: 2023

NIH Submission Brown w/Lenoss Medical: 2023

Achieved 50 Patient Surgeries: 2024

KOL Presentation: American Academy of Orthopedic Surgeons

*Making a Difference in Patient's Lives TODAY*



# A Glimpse to the Future: RI Life Science Hub



RHODE ISLAND  
FOUNDATION

Rhode Island Biotech  
And Life Sciences  
Plan



Prepared by: Damon Cox  
June 2022

STATE

## Pushing to make RI a life science hub, Shekarchi proposes state agency to invest in biotech industry



Patrick Anderson

The Providence Journal

Published 3:56 p.m. ET May 19, 2023



House Speaker K. Joseph Shekarchi is proposing a new quasi-state agency to promote and invest in the [biotechnology industry](#).

2023 -- H 6426

LC003031

STATE OF RHODE ISLAND

IN GENERAL ASSEMBLY

JANUARY SESSION, A.D. 2023

A N A C T

RELATING TO HEALTH AND SAFETY -- THE RHODE ISLAND LIFE SCIENCE HUB  
ACT

Introduced By: Representatives Shekarchi, Blazejewski, Ackerman, Solomon, Edwards,  
Kazarian, Hull, and Baginski

Date Introduced: May 19, 2023

Referred To: House Finance

\$45M Investment to  
Support Life Sciences Hub

Partnerships Across  
Ecosystem  
Including: Commerce, RI Bio,  
NEMIC,  
Universities, Hospitals,  
Life Science Companies



Neil Steinberg, Board Chair





We Have Come So Far...  
With Much Appreciation to  
Carol Malysz, Staff and Fellow  
Board Members



# Annual Meeting: Scientific Advancements & Future Direction

Jaimy Mauricio  
RI Bio Board of Directors

February 15, 2024

# Introduction

- +25 Years as a Rhode Island Resident – (lifelong New Englander)



- +20 Years in Biotech



- Chemical Engineer gone awry into Finance for last 19 Years



- 3<sup>rd</sup> Year as RI Bio BOD Member



- Passionate about:

- New England Sports
- Family
- Life Sciences in RI





# SPECIAL THANKS TO OUR TEAM!



**Carol Malysz**, Executive Director

**Stacey Carter**, Training Director – Project Management Essentials, Advanced Project Management & Reskilling Training

**Kristie Stark** – Creative/Art Director




**Martha Langer** – Biotech Boot Camp Training Director

**Diane Sterrett** – Content & Creative Strategist

**Elizabeth Atalay** – Social Media Director





# RI Bio Mission and Strategic Goals

Grow the Life Sciences Economy in RI & Southeastern New England

RI Bio is the trade group and singular voice of southeastern New England's life sciences. We advance the industry through education, collaboration and advocacy.



Access to  
Capital



Entrepreneur  
Resources



Develop  
Workforce &  
Grow Jobs



Enable  
Infrastructure



Advocate for the  
Industry



Help Make Life  
Sciences  
Accessible to All



# Tremendous Momentum Heading Into 2024


## 2023 RI Bio Key Achievements

- Leadership Skills and Advanced Project Management Training
- Increased awareness of CORES RI directory where researchers can easily search for instruments and services and directly
- Two new advisors appointed to RI Bio Life Science Advisory Council (Sean Marnane - Be Biopharma RJ Panzo, Breakthrough Properties)
- Monthly Women in Science Series, helping to increase women's representation in life sciences
- First-ever two-week intensive Biotech Boot Camp with training partners URI Pharmaceutical Development Institute (PDI) and Skills for Rhode Island's Future
- Record-breaking 20,000+ people attended BIO International annual convention in Boston (June)
- RI Bio joined "Lessons from Other States: How to Grow a Life Sciences Ecosystem & Stay Competitive" at Bio ME Annual Event (Sept)
- **Governor's FY24 budget approved with \$45 million RI Life Science Hub investment (RILSH)**
- Life Sciences Innovation & Showcase Fireside Chat with RI Bio and RILSH Board Chair, Neil Steinberg


2024 Will Be Another Busy and Exciting Year for Life Sciences in RI!!



# Building Our Economy for the Future



House Speaker K. Joseph Shekarchi, Neil Steinberg, and Governor Dan McKee

 The Boston Globe

Could Rhode Island become New England's next life sciences hub?

"facilitate the development of medical advances and scientific breakthroughs" by forming a new group that would "fund and incubate Rhode Island-based life science companies"

House Speaker K. Joseph Shekarchi on introduction of the RILSH Act

"we made a \$45 million life science investment to help attract biotechnology companies from around the world"

"I said that Rhode Island was ready to become a leader in the life science industry. Today's announcement brings us one step closer to reaching our full potential in this growing field"

*Governor Dan McKee's Remarks on Appointment of Neil Steinberg as RILSH Board Chair  
October, 2023*

RI Bio is Well Positioned to be a Strong Partner to the RILSH Initiative



# Positive 2024 Expected for Life Sciences

## Biotech IPO window will 'gradually reopen' in 2024 as M&A remains 'healthy': PwC

By James Waldron · Dec 14, 2023 9:39am



## THE WALL STREET JOURNAL.

### Biotech Acquisitions Heat Up, Giving Venture Capitalists Hope for 2024

Recent acquisitions of small drugmakers are giving biotechnology venture capitalists hope for stabilization in their industry following two years of declining investment.

By *Brian Gormley*

January 11, 2024 ⌚ 3 min read

## Forbes

### Five Major Themes From The 2024 J.P. Morgan Healthcare Conference

Juergen Eckhardt Jan 16, 2024,


1. Most are expecting that access to capital will be easier this year
2. headwinds still face biotech & pharma companies from a range of challenges, including sustained high interest rates, ongoing geopolitical tensions, and the Inflation Reduction Act
3. Artificial intelligence is the talk of the town, but it's still early days
4. The famous GLP-1s (the blockbuster weight loss drugs including Wegovy and Ozempic) dominated much discussion. we will see more pharma companies search for the next generations of these drugs
5. There's growing recognition that China has become a medical innovation powerhouse



# Biotechnology Market Poised for Tremendous Growth

## U.S. Biotechnology Market

Size, by Technology, 2020 - 2030 (USD Billion)




- Global biotechnology market was **valued at USD \$1.55 trillion in 2023**
- projected to grow at a compound annual **growth rate (CAGR) of 14% from 2024 to 2030**
- Value of **\$3.08 trillion projected by 2030**
- BioPharma Reporter analysts **predict that cell and gene therapies**, promising forms of precision medicine, **will be top trends in 2024** aided by the increasing availability of genetic data
- **Artificial intelligence (AI)** has been a helpful tool for gathering bioinformatic data, and it can aid the progress of the study of personalized, or precision, medicine



# CRISPR Gene Editing Rapidly Advancing Science

- **DNA - instruction manual for life**; it encodes fundamental properties of an organism
- **Changing a DNA sequence** in a living cell is **known as genome editing or gene editing**
- For a long time, **this was either impossible or extremely challenging**
- **2012 discovery of CRISPR genome editing** has made this process much easier
- Jennifer Doudna, Emmanuelle Charpentier, and their teams developed a method of repurposing a bacterial immune system called CRISPR —Clustered Regularly Interspaced Short Palindromic Repeats
- **Making breaks in DNA** at precise locations, using a CRISPR-associated enzyme (the Cas9 protein) **like molecular scissors to cut DNA**
- **Allows for editing the genome of living organisms** by adding new fragments of DNA
- **Replacing a disease-causing mutation with a healthy sequence** or make other modifications to the genome
- Alternatively, **this method can be used to “knock out” a gene** entirely

## How Does CRISPR Genome Editing Work?







# CRISPR Gene Editing Historic Approvals!

**Forbes**

## FDA Approves First Crispr Treatment That Might Cure Sickle Cell

Robert Hart Forbes Staff Dec 8, 2023,

**Modern Healthcare**

January 19, 2024 04:00 AM

## Blue Cross first to open sickle cell gene therapy floodgates

 **REUTERS®**

## US FDA approves two gene therapies for sickle cell disease





## U.S. approves first gene-editing treatment, Casgevy, for sickle cell disease

PUBLISHED FRI, DEC 8 2023 11:19 AM EST | UPDATED FRI, DEC 8 2023 4:02 PM EST

### KEY POINTS

- The U.S. Food and Drug Administration has approved Casgevy, the first gene-editing treatment to be marketed in the country.
- Casgevy uses Nobel Prize-winning technology CRISPR to treat sickle cell disease, a blood disorder that affects about 100,000 Americans.
- Vertex Pharmaceuticals and CRISPR Therapeutics co-developed the one-time treatment that will cost \$2.2 million per patient.

**Bloomberg**


## Vertex, Crispr Get Second FDA Approval for Gene Therapy

By [Gerry Smith](#)  
January 16, 2024

- New treatment for beta thalassemia to compete with Bluebird
- FDA approved Casgevy to treat sickle cell disease in December




# Working Together to Expand RI on Hotbed Map!




San Francisco & Northern CA



Boston & Cambridge, MA




San Diego & Southern CA



NY, NJ, PA & **Rhode Island**




Delaware, Maryland, Virginia  
& Washington D.C.



North Carolina



Washington & Oregon



Midwest



Texas





# Leadership & Board



**Carol Malysz, MBA**  
Executive Director, RI Bio



**Patrice Milos, PhD**  
Senior Advisor  
RI Bio Board Chair



**Margaret Farrell, JD**  
Partner, Hinckley Allen



**Michael Katz, PhD**  
Life Science Advisor  
Intellectual Property &  
Economic Development



**Michael Elliott, MBBS, PhD, FRCAP**  
Physician-Scientist, Early-Stage Life Science Investor



**Dom Messerli, MBA**  
CEO, Lenoss Medical



**Guy Asadorian**  
SVP and Private Client  
Advisor, Bank of America  
Private Bank



**Indra Neil Sarkar, PhD**  
President & CEO, Rhode  
Island Quality Institute



**Jeff Vallerga**  
Vice President  
Business Development,  
BIO



**Michelle Wu**  
Medical Device Leader,  
Management Consulting,  
Wu Consulting



**Jaimy Mauricio**  
Senior Director, Financial  
Planning & Analysis,  
Intellia Therapeutics

## Advisory Council

1. Ed Bozzi, PhD
2. Robert Bouthillier
3. Leonard Buckbinder, PhD
4. Chesley M. Chen, MS, MBA
5. Moses Goddard
6. Geraldine Harriman, PhD
7. Scott Keeley
8. Sean Marnane
9. Brian Morley
10. RJ Panzo
11. James Pierce
12. John Thompson, PhD
13. Michelle Wu

# Thank You RI Bio Partners, Sponsors & Members!



Thanks RI Bio Legislative & Policy Committee (including members Amgen, BIO, Bristol Myers Squibb, J&J, Novartis, Pfizer & Vertex)

224 RI Bio Members and Growing!!